Market Overview: Gastric Cancer (27-slide PPT PowerPoint presentation (PPTX)) Preview Image

Click main image to view in full screen.

Market Overview: Gastric Cancer (PowerPoint PPTX Slide Deck)

Name: Market Overview: Gastric Cancer PowerPoint
Brand: pharmzolgas
Price: 299.0 USD
Availability: InStock

PowerPoint (PPTX) 27 Slides

$299.00

Add to Cart

Immediate download

Fully editable PowerPoint

Free lifetime updates

Trusted by over 10,000+ clients

BENEFITS OF DOCUMENT

In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal

DESCRIPTION

This product (Market Overview: Gastric Cancer) is a 27-slide PPT PowerPoint presentation slide deck (PPTX), which you can download immediately upon purchase.

In 2015, major-market sales totaled $1.2 billion for gastric and gastroesophageal junction (GEJ) adenocarcinoma. We expect that major-market sales will rapidly increase over the forecast period, totaling almost $9.5 billion in 2025. This growth will be predominantly fuelled by the approval of seven agents in the indication, and also by Cyramza (Eli Lilly's ramucirumab).

The entry of three PD-1/PD-L1 inhibitors into the gastric and GEJ adenocarcinoma market (Merck & Co.'s Keytruda [pembrolizumab], Bristol Myers-Squibb/Ono Pharmaceutical's Opdivo [nivolumab], and Merck KGaA/Pfizer's avelumab) will significantly drive growth during the forecast period. We also forecast the approval of Yervoy (Bristol Myers-Squibb/Ono Pharmaceutical's ipilimumumab) to be used in conjunction with Opdivo. In addition, we anticipate the launch of a next generation HER2-targeting therapy (Roche/Genentech/Chugai's Perjeta [pertuzumab]), a cancer 'stemness' inhibitor (Boston Biomedical's napabucasin), and a MMP-9 inhibitor (Gilead Sciences's GS-5745). Collectively, these agents will contribute 80% of total sales in the gastric and GEJ adenocarcinoma in 2025.

Introduction
Key Findings
Market Share of Gastric Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PowerPoint Slides: Market Overview: Gastric Cancer PowerPoint (PPTX) Presentation Slide Deck, pharmzolgas

$299.00

Add to Cart

ABOUT THE AUTHOR

Author: pharmzolgas

Additional documents from author: 3

Ask the Author a Question

Must be logged in

Did you know?

The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.

Trusted by over 10,000+ Client Organizations

Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.

Read Customer Testimonials

"One of the great discoveries that I have made for my business is the Flevy library of training materials.

As a Lean Transformation Expert, I am always making presentations to clients on a variety of topics: Training, Transformation, Total Productive Maintenance, Culture, Coaching, Tools, Leadership Behavior, etc. Flevy

... [read more]

– Ed Kemmerling, Senior Lean Transformation Expert at PMG

"The wide selection of frameworks is very useful to me as an independent consultant. In fact, it rivals what I had at my disposal at Big 4 Consulting firms in terms of efficacy and organization."

– Julia T., Consulting Firm Owner (Former Manager at Deloitte and Capgemini)

"Flevy is our 'go to' resource for management material, at an affordable cost. The Flevy library is comprehensive and the content deep, and typically provides a great foundation for us to further develop and tailor our own service offer."

– Chris McCann, Founder at Resilient.World

"Flevy.com has proven to be an invaluable resource library to our Independent Management Consultancy, supporting and enabling us to better serve our enterprise clients.

The value derived from our [FlevyPro] subscription in terms of the business it has helped to gain far exceeds the investment made, making a subscription a no-brainer for any growing consultancy – or in-house strategy team."

– Dean Carlton, Chief Transformation Officer, Global Village Transformations Pty Ltd.

"As a niche strategic consulting firm, Flevy and FlevyPro frameworks and documents are an on-going reference to help us structure our findings and recommendations to our clients as well as improve their clarity, strength, and visual power. For us, it is an invaluable resource to increase our impact and value."

– David Coloma, Consulting Area Manager at Cynertia Consulting

"As a consulting firm, we had been creating subject matter training materials for our people and found the excellent materials on Flevy, which saved us 100's of hours of re-creating what already exists on the Flevy materials we purchased."

– Michael Evans, Managing Director at Newport LLC

"I have used Flevy services for a number of years and have never, ever been disappointed. As a matter of fact, David and his team continue, time after time, to impress me with their willingness to assist and in the real sense of the word. I have concluded in fact

... [read more]

– Roberto Pelliccia, Senior Executive in International Hospitality

"FlevyPro has been a brilliant resource for me, as an independent growth consultant, to access a vast knowledge bank of presentations to support my work with clients. In terms of RoI, the value I received from the very first presentation I downloaded paid for my subscription many times over! The

... [read more]

– Roderick Cameron, Founding Partner at SGFE Ltd